PRA Health Sciences (PRA) is expanding its Early Development Services (EDS) by enhancing its global Phase I patient strategy and increasing its clinical footprint. The company will open an 11,000 sq.-ft. outpatient facility at its Salt Lake City, UT site, focusing on psychiatry, neurology, pain and other therapeutic areas. The new facility includes a dedicated pharmacy, clinical lab and surgical suites.
 
PRA is enhancing patient capabilities and service offerings by implementing operational site models at its Marlton, NJ facility similar to those used at its Patient Pharmacology Services operations in Central and Eastern Europe.
 
The company will also expand its Patient Pharmacology Services into Russia. The first clinical trial application was recently submitted for a rheumatoid arthritis patient study with approval expected in April.
 
Additionally, PRA is expanding its Human Abuse Liability (HAL) study capabilities at its Lenexa, KS site for the conduct of these specialized trials in more than one clinical pharmacology unit.
 
“With PRA conducting more than half of its Phase I/IIa studies in patients vs. volunteers, these initiatives will further enhance our U.S. patient capabilities and service offerings,” said Randall Hein, senior vice president, Clinical Research Services.